Casodex 150-mg Compassionate Use Trial for Subjects with Prostate Cancer

Study identifier:7054US/0014

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Other

Official Title

A Compassionate Use Trial With Bicalutamide (Casodex) 150-mg for Subjects With Prostate Cancer

Medical condition

Adenocarcinoma of the prostate

Phase

Healthy volunteers

None

Study drug

Bicalutamide (Casodex)

Sex

Male

Actual Enrollment

Study type

Expanded Access

Age

18 Years +

Date

Study Start Date: -

Primary Completion Date: -

Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jun 2008 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

Trial Results Summaries
Available here

Contacts

Contact

null AstraZeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com